EUVIMEDEUVIMED entdecken
Open Access

Telomerase inhibition is an effective therapeutic strategy in TERT promoter-mutant glioblastoma models with low tumor volume

Elisa Aquilanti, Lauren Kageler, Jacqueline Watson, Duncan M Baird, Rhiannon E Jones, Marie Hodges, Zsofia M Szegletes, John G Doench, Craig A Strathdee, Jose Ricardo Mc Faline Figueroa, Keith L Ligon, Matthew Beck und 2 weitere

Neuro-Oncology · 2023

DOI: 10.1093/neuonc/noad024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2023. Verfasst von Elisa Aquilanti und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neuro Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Glioblastoma, Telomerase. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Cancer Research UK, NCI NIH HHS, Damon Runyon Cancer Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glioblastoma is one of the most lethal forms of cancer, with 5-year survival rates of only 6%. Glioblastoma-targeted therapeutics have been challenging to develop due to significant inter- and intra-tumoral heterogeneity. Telomerase reverse transcriptase gene (TERT) promoter mutations are the most common known clonal oncogenic mutations in glioblastoma. Telomerase is therefore considered to be a promising therapeutic target against this tumor. However, an important limitation of this strategy is that cell death does not occur immediately after telomerase ablation, but rather after several cell divisions required to reach critically short telomeres. We, therefore, hypothesize that telomerase inhibition would only be effective in glioblastomas with low tumor burden.

Methods

We used CRISPR interference to knock down TERT expression in TERT promoter-mutant glioblastoma cell lines and patient-derived models. We then measured viability using serial proliferation assays. We also assessed for features of telomere crisis by measuring telomere length and chromatin bridge formation. Finally, we used a doxycycline-inducible CRISPR interference system to knock down TERT expression in vivo early and late in tumor development.

Results

Upon TERT inactivation, glioblastoma cells lose their proliferative ability over time and exhibit telomere shortening and chromatin bridge formation. In vivo, survival is only prolonged when TERT knockdown is induced shortly after tumor implantation, but not when the tumor burden is high.

Conclusions

Our results support the idea that telomerase inhibition would be most effective at treating glioblastomas with low tumor burden, for example in the adjuvant setting after surgical debulking and chemoradiation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaTelomeraseHumansTumor BurdenMutationTelomere

Stichwörter der Autor:innen

Telomeraseadjuvant therapyglioblastomatarget validationtargeted therapytumor burden

Substanzen

TelomeraseTERT protein, human

Autor:innen und Institutionen

  • Division of Neuro Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA.
  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA.
  • Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
  • Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK.
  • Genetic Perturbation Platform, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
  • Department of Pathology, Brigham and Women's Hospital, Boston Children's Hospital, Dana Farber Cancer Institute, Boston, Massachusetts, USA.

Förderung

  • Cancer Research UK
  • NCI NIH HHS
  • Damon Runyon Cancer Research Foundation
  • Wales Cancer Research Centre

Zitieren

APA

Aquilanti, E., Kageler, L., Watson, J., Baird, D. M., Jones, R. E., Hodges, M., Szegletes, Z. M., Doench, J. G., Strathdee, C. A., Figueroa, J. R. M. F., Ligon, K. L., Beck, M., Wen, P. Y., & Meyerson, M. (2023). Telomerase inhibition is an effective therapeutic strategy in TERT promoter-mutant glioblastoma models with low tumor volume. Neuro-Oncology. https://doi.org/10.1093/neuonc/noad024

Vancouver

Aquilanti E, Kageler L, Watson J, Baird DM, Jones RE, Hodges M, et al. Telomerase inhibition is an effective therapeutic strategy in TERT promoter-mutant glioblastoma models with low tumor volume. Neuro-Oncology. 2023. doi:10.1093/neuonc/noad024

BibTeX
@article{Aquilanti2023,
  author = {Aquilanti, Elisa and Kageler, Lauren and Watson, Jacqueline and Baird, Duncan M and Jones, Rhiannon E and Hodges, Marie and Szegletes, Zsofia M and Doench, John G and Strathdee, Craig A and Figueroa, Jose Ricardo Mc Faline and Ligon, Keith L and Beck, Matthew and Wen, Patrick Y and Meyerson, Matthew},
  title = {Telomerase inhibition is an effective therapeutic strategy in TERT promoter-mutant glioblastoma models with low tumor volume},
  journal = {Neuro-Oncology},
  year = {2023},
  doi = {10.1093/neuonc/noad024}
}
Kostenlos starten →